Incyte Corporation ($INCY) Stock Forecast: Up 5.0% Today

What is Incyte Corporation?

Incyte Corporation (INCY) Market: Incyte (INCY) is a biopharmaceutical company focusing on oncology and inflammation & autoimmunity. The company recently exceeded quarterly earnings expectations, reporting an EPS of $2.26 against an estimated $1.65, with revenues up 20% year-over-year. Despite strong quarterly results, there is mixed analyst sentiment with an average "Hold" rating.

Why is Incyte Corporation going up?

INCY stock is up 5.0% on Dec 19, 2025 18:15

• The strong bullish movement in Incyte's stock today could be attributed to the positive quarterly results, beating analyst EPS and revenue estimates.
• The recent approval for Minjuvi in Europe, a chemotherapy-free immunotherapy for follicular lymphoma, has likely boosted investor confidence in Incyte's oncology portfolio.
• The significant insider selling by Incyte's EVP, Michael James Morrissey, might have initially raised concerns, but the overall market sentiment seems to have focused more on the company's recent achievements and future pipeline potential.
• Incyte's upcoming presentation at the J. P. Morgan Healthcare Conference could also be generating optimism among investors regarding the company's future outlook and growth prospects.

INCY Price Chart

INCY Technical Analysis

INCY News

CRISPR Therapeutics (CRSP): Reassessing Valuation After a 13% Pullback and Strong Year‑to‑Date Gains

CRISPR Therapeutics (CRSP) has experienced a 13% pullback recently, prompting a re-evaluation of its stock despite strong year-to-date gains of over 32%. The company's price-to-book ratio of 2.7x suggests it's fairly valued compared to peers, but a Discounted Cash Flow (DCF) model indicates a potentially higher fair value of $125.93 against its current $54.74. Investors are left to consider whether the market has fully priced in its gene-editing pipeline and CASGEVY rollout or if it remains undervalued.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/crispr-therapeutics-crsp-reassessing-valuation-after-a-13-pu

Michael James Morrissey Sells 54,008 Shares of Incyte (NASDAQ:INCY) Stock

Michael James Morrissey, EVP of Incyte Corporation, sold a significant portion of his holdings, including 54,008 shares on December 16th and an additional 4,323 shares on December 17th, reducing his ownership by about 62.92%. These sales occurred amidst strong quarterly results for Incyte, which reported beating analyst EPS and revenue estimates. Despite institutional ownership of nearly 97%, analyst sentiment for the stock is mixed, with an average "Hold" rating.

https://www.marketbeat.com/instant-alerts/michael-james-morrissey-sells-54008-shares-of-incyte-nasdaqincy-stock-2025-12-18/

Michael James Morrissey Sells 4,323 Shares of Incyte (NASDAQ:INCY) Stock

Incyte EVP Michael James Morrissey recently sold 4,323 shares of the company's stock for over $420,000, reducing his stake by 13.58%, following a larger sale of 54,008 shares the previous day. The biopharmaceutical company recently exceeded quarterly earnings expectations, reporting an EPS of $2.26 against an estimated $1.65, with revenues up 20% year-over-year. Analysts currently hold a consensus "Hold" rating for Incyte, with an average price target of $99.07.

https://www.marketbeat.com/instant-alerts/michael-james-morrissey-sells-4323-shares-of-incyte-nasdaqincy-stock-2025-12-18/

First Chemotherapy-Free CD19/CD20 Lymphoma Regimen In Europe Might Change The Case For Investing In Incyte (INCY)

Incyte recently secured European Commission approval for Minjuvi, broadening its oncology presence with the first chemotherapy-free, dual-targeted immunotherapy for follicular lymphoma. This development strengthens Incyte's oncology portfolio, but the company's investment narrative still hinges on the performance of Opzelura and Jakafi, while facing risks from potential revenue erosion of the latter. Investors should consider how this approval impacts Incyte's overall financial health and future pipeline potential.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-incy/incyte/news/first-chemotherapy-free-cd19cd20-lymphoma-regimen-in-europe

Incyte to Present at Upcoming Investor Conference

Incyte (Nasdaq: INCY) announced it will present at the 44th Annual J. P. Morgan Healthcare Conference on Monday, January 12, 2026, at 8:15 am (PST). The presentation will be available via live webcast and replay on Investor.Incyte.com. Incyte is a global biopharmaceutical company focusing on oncology and inflammation & autoimmunity.

https://www.businesswire.com/news/home/20251218287907/en/Incyte-to-Present-at-Upcoming-Investor-Conference

Trending Today

Toncoin ($TON) Crypto Forecast: Up 5.1% Today

Marsh & McLennan Companies Inc. ($MMC) Stock Forecast: Down 0.3% Today

Tilray Inc. ($TLRY) Stock Forecast: Down 5.3% Today

Nike Inc. ($NKE) Stock Forecast: Up 5.3% Today

Groupon Inc. ($GRPN) Stock Forecast: Up 5.0% Today

Hologic Inc. ($HOLX) Stock Forecast: Down 0.6% Today

Micron Technology Inc. ($MU) Stock Forecast: Up 5.3% Today

FuelCell Energy ($FCEL) Stock Forecast: Down 6.1% Today

Prime Medicine ($PRME) Stock Forecast: Down 5.0% Today

Moderna Inc. ($MRNA) Stock Forecast: Down 5.7% Today

Incyte Corporation Price History

30.06.2025 - INCY Stock was up 5.9%

• INCY stock experienced a strong bullish movement today.
• The bullish trend can be attributed to Incyte reporting better-than-expected Q2 earnings and revenues, driven by strong sales of Jakafi and Opzelura.
• The company's upward revisions in guidance for Jakafi demand and other oncology products have also contributed to the positive market sentiment.
• Investors are optimistic about the company's performance in the upcoming quarters, especially with the success of their key products and new launches driving revenues.

28.09.2025 - INCY Stock was down 5.0%

• The bearish movement in INCY stock today could be attributed to profit-taking by investors ahead of the company's Q3 earnings report.
• Despite expectations of strong performance driven by key products like Jakafi and Opzelura, investors may have been cautious due to uncertainties surrounding new product launches like Niktimvo.
• The anticipation of a potential earnings beat may have already been priced into the stock, leading to a sell-off post-news headlines.
• Market sentiment may have also been influenced by broader industry trends or economic indicators impacting the biopharmaceutical sector.

29.06.2025 - INCY Stock was up 9.1%

• Incyte (INCY) exceeded Q2 earnings and revenue expectations, showcasing a robust performance in the quarter.
• The revenue growth of 16% to $1.22B and EPS of $1.57 compared to a loss of $1.82 YoY contributed to the bullish sentiment.
• Upward revisions in Jakafi guidance to $3-$3.05 billion for 2025, along with positive outlooks on other oncology products, fueled investor optimism.
• The strong performance in Q2, driven by successful products like Jakafi, Opzelura, and new launches, led to increased confidence in Incyte's future prospects, resulting in the bullish market movement.

29.06.2025 - INCY Stock was up 6.0%

• Expectations of a strong Q2 performance with key products like Jakafi, Opzelura, and Niktimvo driving revenues likely contributed to the bullish movement.
• Anticipation of an earnings beat in the upcoming report could have attracted investors to buy INCY stock, leading to the bullish movement.
• Positive sentiment surrounding the company's product portfolio and potential growth prospects might have fueled investor confidence, pushing the stock higher.

26.05.2025 - INCY Stock was up 5.0%

• The FDA approval for the expanded use of Monjuvi in lymphoma is a significant milestone for Incyte, underscoring the company's commitment to developing effective treatments for challenging conditions.
• The approval of Monjuvi in combination with rituximab and lenalidomide for relapsed/refractory follicular lymphoma creates a new revenue stream for Incyte and strengthens its position in the oncology market.
• The strong bullish movement in INCY stock today is likely influenced by this positive development, as investors react favorably to the company's growth prospects and expanding product portfolio in the competitive biopharmaceutical industry.

04.10.2025 - INCY Stock was up 9.1%

• The bullish movement in Incyte's stock is likely due to positive advancements in their partnership with Prelude Therapeutics for potential disease-modifying treatments and the company's robust financial performance in Q3, surpassing revenue expectations and demonstrating growth potential in the face of patent concerns. These factors, combining positive developments and financial success, probably boosted investor optimism and led to the stock's upward trajectory.

19.11.2025 - INCY Stock was up 5.0%

• The strong bullish movement in Incyte's stock today could be attributed to the positive quarterly results, beating analyst EPS and revenue estimates.
• The recent approval for Minjuvi in Europe, a chemotherapy-free immunotherapy for follicular lymphoma, has likely boosted investor confidence in Incyte's oncology portfolio.
• The significant insider selling by Incyte's EVP, Michael James Morrissey, might have initially raised concerns, but the overall market sentiment seems to have focused more on the company's recent achievements and future pipeline potential.
• Incyte's upcoming presentation at the J. P. Morgan Healthcare Conference could also be generating optimism among investors regarding the company's future outlook and growth prospects.

17.09.2025 - INCY Stock was down 5.7%

• The comparison between INCY and ARGX for better value stock might have highlighted weaknesses in INCY's financials or growth prospects, leading to a bearish movement.
• Investors may have reevaluated INCY's position in the market and decided to shift their investments towards other companies with more promising value propositions.
• This assessment could have triggered a sell-off in INCY's stock, driving the bearish movement observed today.
• It is essential for investors to carefully analyze the underlying factors driving such comparisons to make informed decisions about their investment strategies.

08.11.2025 - INCY Stock was down 1.4%

• Today's downward movement in Incyte Corporation's stock could be linked to profit-taking by investors following a string of positive developments.
• In spite of recent upgrades and promising clinical data shared at a medical conference, the stock may have dipped as investors secured profits.
• The initial surge in stock price due to increased investments from institutional shareholders like American Century Companies Inc. and Invesco Ltd. might have been counterbalanced by subsequent selling pressure.
• The broader market sentiment towards biopharmaceutical firms and the healthcare industry could have also played a role in the stock's decline today.

11.02.2025 - INCY Stock was down 5.7%

• INCY is the stock symbol for Incyte, a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics.
• ASSESSMENT:
• The bearish movement in INCY stock today could be due to profit-taking by investors after a strong positive run following the news of Opzelura's superior efficacy in prurigo nodularis studies.
• Despite the positive data from the phase III studies and the encouraging efficacy of their partnered FDA-approved drug, investors may have been expecting even better results, leading to a sell-off.
• The market might be reacting to concerns about the sustainability of the positive outcomes reported, leading to a temporary dip in the stock price.

17.02.2025 - INCY Stock was up 5.1%

• Today's surge in Incyte's stock value is a direct result of the successful outcomes from the Phase 3 STOP-HS trials for their latest chronic skin disease medication, Povorcitinib.
• Initial hesitance in the stock price during pre-market trading, attributed to mixed reviews of the trial data, was overshadowed by the drug's effectiveness in patients previously treated with biologics, along with the positive rates of HiSCR50.
• Furthermore, the positive reception towards Incyte's pioneering treatments is reinforced by the promising results of an FDA-approved drug, a collaboration with Eli Lilly, which showed substantial efficacy in young patients grappling with patchy hair loss.
• The continuous progress in Incyte's product pipeline and its commitment to addressing unmet medical needs have instilled confidence in investors regarding the company's potential for future growth, fueling the optimistic upturn in the stock value.

29.09.2025 - INCY Stock was up 7.2%

• Incyte Corporation demonstrated robust growth in third-quarter revenue, exceeding consensus estimates and displaying a 20% year-over-year increase in total revenues.
• The strong performance in Q3 was attributed to higher sales figures of key products like Jakafi, Opzelura, and recent launches, indicating positive revenue prospects for the company.
• Despite concerns regarding a patent expiration in 2028, the company's recent quarter results have bolstered investor confidence, resulting in a bullish market trend for INCY stock today.